Theriva Biologics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TOVX NYSE American 2836 therivabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Theriva Biologics, Inc.

Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design - Dec 30th, 2025 6:05 am
Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - Dec 29th, 2025 6:00 am
Theriva Biologics: Q3 Earnings Snapshot - Nov 12th, 2025 6:16 am
Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results - Nov 12th, 2025 6:00 am
Theriva Biologics Provides Response to Unusual Market Action - Oct 24th, 2025 12:31 pm
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds - Oct 16th, 2025 6:11 am
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings - Oct 13th, 2025 6:00 am
Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) - Oct 6th, 2025 6:00 am
Theriva Biologics: Q2 Earnings Snapshot - Aug 11th, 2025 4:14 pm
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - Aug 11th, 2025 6:00 am
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer - May 27th, 2025 6:00 am
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - May 14th, 2025 6:40 am
Theriva Biologics: Q1 Earnings Snapshot - May 14th, 2025 6:22 am
Theriva Biologics Announces Closing of $7.5 Million Public Offering - May 8th, 2025 2:30 pm
Theriva Biologics Announces Pricing of $7.5 Million Public Offering - May 7th, 2025 7:17 am
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - May 7th, 2025 5:00 am
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - Apr 10th, 2025 6:00 am
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) - Mar 31st, 2025 6:00 am
Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - Mar 19th, 2025 6:10 am
Q1 Virtual Investor Summit: On-Demand Presentations Now Live - Mar 18th, 2025 1:30 pm